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Background: Alzheimer’s disease (AD) is characterized by the deposition of insoluble amyloid plaques in the
neuropil composed of highly stable, self-assembled Amyloid-beta (Aβ) fibrils. Copper has been implicated to play a
role in Alzheimer’s disease. Dimers of Aβ have been isolated from AD brain and have been shown to be neurotoxic.
Results: We have investigated the formation of dityrosine cross-links in Aβ42 formed by covalent ortho-ortho coupling
of two tyrosine residues under conditions of oxidative stress with elevated copper and shown that dityrosine can be
formed in vitro in Aβ oligomers and fibrils and that these links further stabilize the fibrils. Dityrosine crosslinking was
present in internalized Aβ in cell cultures treated with oligomeric Aβ42 using a specific antibody for dityrosine by
immunogold labeling transmission electron microscopy. Results also revealed the prevalence of dityrosine crosslinks in
amyloid plaques in brain tissue and in cerebrospinal fluid from AD patients.
Conclusions: Aβ dimers may be stabilized by dityrosine crosslinking. These results indicate that dityrosine cross-links
may play an important role in the pathogenesis of Alzheimer’s disease and can be generated by reactive oxygen
species catalyzed by Cu2+ ions. The observation of increased Aβ and dityrosine in CSF from AD patients suggests that
this could be used as a potential biomarker of oxidative stress in AD.
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Amyloid fibrils are associated with a large number of dis-
eases in which proteins or peptides abnormally assemble
to form insoluble amyloid deposits in the tissues. The
amyloid-β (Aβ) protein is an amyloidogenic peptide that
is cleaved from the amyloid precursor protein (APP)
[1]. The Aβ peptide is present in all individuals but in
Alzheimer’s disease (AD) it abnormally assembles and
deposits in amyloid plaques in the neuropil [1]. Amyloid
fibrils are characterized by their significant insolubility
and resistance to degradation [2]. Aβ is thought to play a
central role in AD pathology since several familial AD
mutations are related to changes within the Aβ peptide
itself, or in the proteins affecting its production [3]. Aβ42
contains a tyrosine at position 10, located close to the
fibrillogenic core of the peptide [4]. However, the tyrosine* Correspondence: L.C.Serpell@sussex.ac.uk
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stated.residue can oxidize to many different modification prod-
ucts, such as nitrotyrosine and dityrosine [5].
Redox-active metal ions, such as Cu2+ and Fe3+, have
been suggested to play a role in the pathogenesis of
many neurodegenerative disorders, including AD and
Parkinson’s disease [6]. There is a large body of evidence
pointing to the importance of interactions between
redox-active metal ions and proteins in the pathogenesis
of many diseases [7-9]. Two mechanisms have been sug-
gested to explain the abnormalities of these interactions
in neural tissue: (a) the aggregation of protein mediated
by redox-active metal ions; and (b) metal catalyzed oxi-
dation reactions (MCO) [10]. Metal-protein interactions
could result in oxidative stress through generation of
reactive-oxygen species (ROS), which in turn induces
lipid peroxidation, protein oxidation, and DNA damage
[11,12]. The consequences of protein oxidation are pro-
tein cross-links, amino acid side chain modifications,
and protein fragmentation [11,13]. The oxidative modifi-
cation of proteins by ROS has been classified in two
groups; (a) Global oxidative modifications, which includel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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eral products; (b) Specific oxidative modifications which
are very specific in both the residue oxidized and the
product generated, e.g. oxidation of tyrosine residue to
give dityrosine [14].
High concentrations of copper (0.4 mM), zinc (1 mM),
and iron (1 mM) have been found in amyloid plaques and
have been implicated in the pathogenesis of AD [10,15].
Several studies have shown that Aβ is able to reduce cop-
per and iron ions and to generate ROS [7,9,12,16]. The
most common in vivo source of ROS is hydrogen peroxide
(H2O2) breakdown according to the Fenton reaction,
which is catalyzed by a metal-protein complex [7].
The formation of dityrosine cross-links is one of the
oxidative modifications that have been implicated in me-
diating toxicity of Aβ through Aβ aggregation. Several
studies [17-20] demonstrate that Aβ can undergo dityro-
sine formation via two common biochemical pathways.
One of them is peroxidase-catalyzed cross-linked tyro-
sine and the second mechanism is metal-catalyzed
oxidative tyrosyl radical formation. The mechanism of
dityrosine cross-links involves tyrosyl radical formation,
followed by radical isomerisation and then diradical re-
action, and finally enolisation [21]. On the other hand,
Smith et al. demonstrated that the generation of the Aβ
toxic species is modulated by the concentration of Cu2+
ions and the ability to form intermolecular histidine
bridges [22]. Interestingly dityrosine has been selected as
a biomarker for oxidative stress of proteins due to its
chemical stability, as it remains unchanged by exposure
to oxygen and high pH [23]. Furthermore, it is highly re-
sistant to acid hydrolysis and proteases [24,25].
Here we have explored the in vitro formation of dityro-
sine in Aβ42 using Cu2+ ions and H2O2 in both early olig-
omeric Aβ42 and preformed Aβ42 fibrils and examined
the effect of the cross-linking on the structure of the fibrils
and the assembly competence of the oligomers. We have
shown that dityrosine formation is inducible in both
soluble and fibrillar Aβ42 and suggest that the formation
of crosslinks may stabilize assemblies. Neuroblastoma cell
cultures treated with non-oxidized Aβ42 oligomers showed
formation of Aβ assemblies containing dityrosine sur-
rounding and sometimes internalized into the cells.
Examination of samples from AD patients revealed the
presence of dityrosine linkages within amyloid plaques
and its colocalisation with Aβ in cerebrospinal fluid
pointing to a physiological relevance of dityrosine cross-
linking in AD, and highlighting the importance of oxida-
tive stress in the disease.
Methods
Synthesis of a dityrosine standard
A dityrosine standard was synthesized according to mo-
difications of established procedures [20,26]. 20 units ofhorse radish peroxidase (HRP) were added to a clear so-
lution of (10 mM) N-acetyl-3,5-diiodo-L-tyrosine in
40 ml of (0.1 M) phosphate buffer pH 6.0 containing
10% of acetonitrile then mixed gently. Immediately,
0.48 ml of (1 M) H2O2 was added then the reaction mix-
ture was stirred gently for 60 min at 24°C, quenched
with 1.2 ml of (1 M) NaHSO3 and the pH of the mixture
was adjusted to 7.5 with (1 M) NaOH. After stirring for
10 min the mixture was acidified to pH 3.0 with (2 M)
KHSO4 and then extracted with ethyl acetate. The com-
bined organic residues were concentrated under vacuum
to give a tan residue, which was purified by flash chroma-
tography to give 3,3′-diiodo-N,N’-diacetyl di-L-tyrosine.
In turn, 3,3′-diiodo-N,N’-diacetyl di-L-tyrosine was hydro-
genated in 50% methanol:acetic acid to give N,N′-diacetyl
di-L-tyrosine, which was heated at reflux in a 1:1 mixture
of tetrahydrofuran and concentrated HCl to give dityro-
sine. Gel filtration on sephadex G-10 was carried out in
order to remove the salt and further purification was
achieved using RP-HPLC. Finally, the purified dityrosine
was dried using a freeze dryer (Edwards, England), and
analyzed using a Bruker Daltonics APEX III 4.7 Tesla
Fourier Transform ion cyclotron resonance mass spec-
trometer (FT-ICR-MS) with electrospray source and
found to be m/z 361.1392 compared with calculated
m/z 361.1394. NMR was carried out and the 1H NMR
spectrum contained six proton signals with chemical
shifts of: 7.30 ppm (H, d), 7.21 ppm (H, s), 7.07 ppm (H,
d), 4.26 ppm (H, m), 3.35 ppm (H, dd), and 3,26 ppm
(H’, dd). This spectrum is very similar to that published
elsewhere [27-29].
Preparation of fibrillar and oligomeric Aβ42
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) Aβ42 was pur-
chased from rPeptide (Bogart, GA, USA). To remove pre-
formed aggregates, the peptide was prepared as previously
described [30] using HFIP >99.0%, followed by anhydrous
DMSO (Fisher Sci.) and then buffer exchanged using a
desalting column to remove the solvents. The concentra-
tion was determined using a molar extinction coefficient
of 1490 M-1 cm-1 and the absorbance was measured at a
wavelength of 280 nm using an Eppendorf Biophotometer
(Eppendorf UK Ltd., Cambridge, UK). The resulting stock
peptide concentrations of 90–130 μM were used immedi-
ately for early oligomeric Aβ42 experiments, or incubated
for at least two weeks at room temperature (22°C) in order
to generate Aβ42 fibrils (confirmed using TEM).
Oxidation of fibrillar and early oligomeric Aβ42
Stock solutions of soluble or fibrillar Aβ42 were diluted
in (a) water or (b) 50 mM phosphate buffer pH 7.4 to
obtain 20 μM Aβ42 as a final concentration and incu-
bated with or without (20 μM) Cu2+ and (0.5 mM) H2O2
at 37°C with agitation in a shaking incubator for three
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concentration of 250 μM EDTA.
Fluorescence spectroscopy
The fibrils were resuspended by agitation. Fluorescence
spectra were recorded over time. Fluorescence measure-
ments were carried out on a Varian Cary Eclipse fluorim-
eter (Varian Ltd., Oxford, UK) using a 1 cm path length
quartz cuvette (Starna, Essex, UK), and dityrosine fluores-
cence was monitored using an excitation wavelength of
320 nm. Dityrosine emission was monitored between
340 and 500 nm, with maximum fluorescence intensity
at around 400–420 nm at a controlled temperature of
21°C. Tyrosine fluorescence signal was monitored using
an excitation wavelength of 280 nm and emission wave-
length of 305 nm. Excitation and emission slits were
both set to 10 nm, and the scan rate was set to 300 nm/min
with 2.5 nm data intervals and an averaging time of 0.5 s.
The photomultiplier tube detector voltage was set at 500 V.
To detect dityrosine fluorescence at early time points, 130 μl
of the reaction mixture was removed and EDTA was
added to final concentration of 250 μM.
Sample preparation for LC-ESIMS/MS analysis
Oxidized Aβ42 fibrils prepared in water were lyophilized
using a Modulyo 4 K Freeze Dryer (Edwards, Crawley,
England), and then hydrolysed using evacuated sealed
tubes under acidic conditions of (6 M) HCl, 10% TFA,
and 1% phenol at 110°C for 48 h. The resulting hydrolys-
ate was then dried under nitrogen gas, dissolved in
100 μl of 0.1% formic acid in water and then filtered
using a Millipore 0.22 μm filter into a 0.2 ml tube.
Detection of dityrosine by LC-ESIMS/MS
20 μl of oxidized Aβ42 fibril hydrolysate was injected on
to a Phenomenex Gemini 3u C6-phenyl 110 (150 mm ×
4.6 mm, 3 micron) column using a High performance li-
quid chromatography (HPLC) system (Waters Alliance
2695, Ireland) coupled to the mass spectrometer (Micro-
Mass Quattro Premier, Waters, Ireland) operated in the
multiple reaction-monitoring (MRM) mode with positive
electrospray ionisation (ESI). The solvents for the mobile
phase were A: 0.1% formic acid in water; and solvent B:
0.1% formic acid in acetonitrile. The gradients were as fol-
lows: t = 0 min, 0% B; t = 1 min, 0% B; t = 15 min, 100% B;
t = 20 min, 100% B; t = 25 min, 0% B; t = 30 min, 0% B,
and the flow rate was 200 μl/min. Mass spectrometric de-
tection was performed by positive electrospray ionisation
(ESI) tandem mass spectrometry on a triple quadrupole
mass spectrometer (MicroMass Quattro Premier, Waters,
Ireland). The conditions for the mass spectrometer were
as follows; electrospray ionization spray voltage 3.5 kV, the
cone voltage 35 V, the source temperature at 100°C,
whereas the desolvation temperature was 400°C. Argonwas used as the collision gas at 5.95 e-003 mbar at 26 ev
collision energy.
Thioflavin T fluorescence assay
The fibril formation of Aβ42 was monitored using ThT
fluorescence. A 0.2 μm filtered (3.14 mM) aqueous ThT
stock solution was prepared and stored frozen at −20°C
in 1–10 μl aliquots until required. ThT was added to a
10 μM Aβ42 sample (50 mM phosphate buffer pH 7.4)
to a final concentration of 20 μM, gently vortexed, and
allowed to bind for 3 minutes before a reading was
taken. Using a microvolume cuvette of 1 cm path length,
ThT fluorescence was measured using a Varian Cary
Eclipse fluorimeter (Varian, Oxford, UK) with excitation
wavelength of 450 nm. The emission spectrum was re-
corded between 460–600 nm at 21°C. Phosphate buffer
baselines were subtracted from the data. Excitation and
emission slits were set to 5 nm and 10 nm respectively.
The scan rate was 600 nm/min with 1 nm data intervals
and an averaging time of 0.1 s. The voltage on the
photomultiplier tube was set to high (800 v) and experi-
ments were carried out in triplicate to confirm trends.
Negative stain TEM
Four microliter aliquots of Aβ42 samples were placed
onto Formvar/carbon coated 400-mesh copper grids
(Agar Scientific, Essex, UK) for 1 min, and the excess
was removed using filter paper. Subsequently the grid
was washed using 4 μl of Milli-Q water filtered with
0.22 μm filter and blotted dry, then negatively stained
twice with 4 μl of filtered 2% (w/v) uranyl acetate for
1 min and blotted dry. The grid was allowed to air-dry
before examination on a Hitachi 7100 transmission elec-
tron microscope (Hitachi, Germany) fitted with a Gatan
Ultrascan 1000 CCD camera (Gatan, Abingdon, UK) at
an operating voltage of 100 kV.
Dityrosine cross-linked Aβ42 fibril stability
Aβ42 was assembled under oxidizing and non-oxidizing
conditions and stored at −80°C for more than one year
and the dityrosine content was assessed using fluores-
cence with an excitation wavelength of 320 nm as de-
scribed above. Both oxidized and non-oxidized Aβ42
fibrils were centrifuged for 30 min at 16,000 RCF at 4°C,
and then the soluble Aβ42 concentration in the super-
natant was measured using absorbance at 280 nm (as
described for peptide preparation). TEM grids were pre-
pared to examine the Aβ42 fibrils in the pellet. The oxi-
dized and non-oxidized fibrils were then dissolved in
80% v/v formic acid with agitation. The resulting solution
was centrifuged using the same conditions above, and
again the dissolved Aβ42 concentration was determined.
TEM grids for the pellet were prepared to examine the
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SDS gel electrophoresis
Aβ was incubated under oxidizing conditions as before
for 10 mins and then quenched using EDTA. Oxidized
and non-oxidized Aβ peptides were separated by SDS-
PAGE and analyzed by densitometry. Samples were
heated to 85°C for 5 min and then 5 μl added to each
well of a Novex® 1.0 mm 10-20% Tricine gel, (Life Tech-
nologies Ltd, Paisley, UK). Oxidized and nonoxidized
samples were run on the XCell SureLock® Mini-Cell with
a PowerEase® 500 power supply (Life Technologies Ltd,
Paisley, UK). A voltage of 125 V, an expected start
current of 80 mA/gel and an expected end current of
40 mA/gel was applied. The gel was stained using Silver-
Quest™ Silver staining kit (Life Technologies Ltd, Paisley,
UK) following the manufacturers protocol provided.
Briefly, the gel was fixed for 60 min in 40% ethanol, 10%
acetic acid, and 50% milliQ water, then rinsed in 30%
ethanol (10 min), incubated in sensitizer solution
(10 min), rinsed in 30% ethanol (10 min), washed with
milliQ water (10 min), incubated in silver stain (15 min),
and washed again with milliQ water (60 sec). The gel
was then incubated in developer (5–10 min). Finally, the
stopper was directly added to the stained gel (10 min)
and subsequently washed with milliQ water (10 min).
The gel was scanned at 8 bit with 600 dpi resolution.
The densitometry was calculated using ImageJ.
Immunogold labeling, negative stain TEM (for fibrils and
cerebrospinal fluid)
A modified phosphate-buffered saline, pH 8.2, contain-
ing 1% BSA, 500 μl/l Tween-20, 10 mM Na EDTA, and
0.2 g/l NaN3 (henceforward termed PBS+), was used
throughout all the following procedures for all dilutions
of antibodies and secondary gold probes. Aβ42 fibrils
were oxidized and assembled as described in oxidation
of fibrillar and early oligomeric Aβ42 and immunogold-
labeled ‘on grid’ for dityrosine according to established
methods. A monoclonal anti-dityrosine antibody was
purchased from Japan Institute for the Control of Aging
(JaICA) Shizuoka, Japan (cat. no. MDT-020P). The anti-
body has been fully characterised and shown to be
highly specific and does not show any cross-reactivityTable 1 Demographic details of cases from which cerebrospin
Case Age Sex Patho
AD 1 68 M Alzhe
AD 2 93 F Alzhe
AD 3 91 M Alzhe
Normal 1 89 F Contr
Normal 2 92 F Contrwith other tyrosine derivatives such as nitrotyrosine,
chlorotyrosine [31]. The antibody will detect any protein
containing dityrosine. Briefly, 4 μl aliquots of the oxidized
Aβ42 fibrils were pipetted onto Formvar/carbon coated
400 mesh copper TEM support grids (Agar Scientific,
Essex, UK), left for 1 min, the excess was removed with fil-
ter paper, and then blocked in normal goat serum (1:10
in PBS+) for 15 min. Grids were then incubated with
(10 μg/ml IgG) mouse dityrosine monoclonal antibody
(JaICA, Shizuoka, Japan) for 2 h at room temperature,
rinsed in 3×2 min PBS+, and then immunolabeled in a
10 nm gold particle-conjugated goat anti-mouse IgG
secondary probe (GaM10 British BioCell International,
Cardiff, UK; 1:10 dilution) for 1 h at room temperature.
After 5×2 min PBS + and 5×2 min distilled water rinses,
the grids were negatively stained as described in nega-
tive stain TEM.
Cerebrospinal fluid (CSF) samples from AD patients
and control age matched subjects were obtained from the
London Neurodegenerative Diseases Brain Bank. CSF was
removed according to Local Ethics Committee guidelines,
and informed consent for brain donation was obtained
from the next of kin (see Table 1). The samples were
stored at −80°C in a locked freezer until needed. When re-
quired, they were diluted with Milli-Q water (1:3). A
rabbit antibody raised against N-terminus of Aβ42 (1–6)
(AB5078P, Chemicon, Temecula, CA, USA) was used to
detect Aβ in the following experiments. This antibody has
been shown not to cross react with APP [32]. Diluted CSF
samples were double-immunogold-labeled for dityrosine
and Aβ42 as described above, except grids were incubated
in a mixture of (10 μg/ml IgG) anti Aβ42 rabbit polyclonal
antibody AB5078P (Chemicon, Temecula, CA, USA) and
(10 μg/ml IgG) mouse monoclonal dityrosine antibody
(Japan Institute for the Control of Aging JaICA, Shizuoka,
Japan). A mixture of 5 nm gold particle-conjugated goat
anti-rabbit IgG (GaR5 British BioCell International, Cardiff,
UK) and 15 nm gold particle-conjugated GaM (British
BioCell International, Cardiff, UK; 1:10 dilution) was
used for the secondary gold probe.
Immunogold Labeling TEM of sections
AD and aged matched control brain from middle frontal
gyrus tissues were obtained from London Neurodegenera-
tive Diseases Brain Bank. Tissue was removed accordingal fluid were obtained
logical diagnosis
imer’s disease HP-tau stage 6 with mild to moderate amyloid angiopathy
imer’s disease HP-tau stage 6 with moderate amyloid angiopathy
imer’s disease HP-tau stage 6 with moderate amyloid angiopathy
ol case but with hypoxic-type changes and amyloid angiopathy
ol-some amyloid angiopathy
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sent for brain donation was obtained from the next of kin
(see Table 2) and stored at −80°C until required. SH-SY5Y
cells were incubated for 24 hours with a final concentra-
tion of freshly prepared 10 μM Aβ42 and controls cells
were administered with buffer only (prepared as described
in Soura et al., 2012 [33]). SH-SY5Y cells and brain tissues
were prepared for immunogold labeling TEM by minimal,
cold fixation and embedding protocols, as previously de-
scribed in Soura et al., (2012) [33] and Thorpe et al.,
(2001) [34], respectively. Immunogold labeling was per-
formed using an established methodology [35], with PBS +
buffer being used for all dilutions of immunoreagents
and for rinsing. Thin sections were collected upon TEM
support grids, then incubated with normal goat serum
(1:10 dilution) for 30 min at room temperature to block
non-specific secondary antibody binding. In turn, grids
were labeled with (10 μg/ml IgG) anti-dityrosine mouse
monoclonal antibody (Japan Institute for the Control of
Aging JaICA, Shizuoka, Japan) or double-labeled using a
mixture of (10 μg/ml IgG) anti-Aβ42 rabbit polyclonal
antibody AB5078P (Chemicon, Temecula, CA, USA)
and (10 μg/ml IgG) anti-dityrosine mouse monoclonal
antibody and incubated overnight at 4°C. After 3×2 min
PBS + rinses, sections were then immunolabeled with
GaM10 or a mixture of GaR5 and GaM10 secondary
probes (both 1:10 dilution), respectively, for 1 h at room
temperature. After 3×10 min PBS + and 4×5 min distilled
water rinses, the grids were post-stained in 0.22 μm-
filtered 0.5% (w/v) aqueous uranyl acetate for 1 h. Labelling
controls were performed using serial sections and
using the identical procedure and IgG concentrations,
with an irrelevant antibody to hair cell antigen (MAb10)
(Richardson et al., personal communication).
The grids were examined on a Hitachi 7100 TEM
(Hitachi, Germany) fitted with a Gatan Ultrascan 1000
CCD camera (Gatan, Abingdon, UK), and operating with
a voltage of 100 kV.
Analysis of immunogold labeled sections
Counting and size analyses of immunogold particles
were performed using in house software written in Matlab.Table 2 Demographic details of cases from which middle fron
Case Age Sex Patho
Normal 1 89 F Contr
Normal 3 80 F Contr
AD 1 68 M Alzhe
AD 2 93 F Alzhe
AD 3 91 M Alzhe
AD 4 86 F Alzhe
AD 5 77 F AlzheBriefly, raw digital electron micrograph images files
were uploaded and circular particles detected using in-
built Matlab circular Hough transforms functions. The
detection range diameter was calculated from user input
and conversion to pixel size values read from the image
header. 15 or 10 nm gold particles were distinguished
from 5 nm particles based on a user-selected threshold
of 7 nm.
Results
In vitro oxidation of Aβ42 resulting in the formation of
dityrosine cross-links
Aβ42 amyloid fibrils were preformed in water and incu-
bated for up to three days in the presence of Cu2+ and
H202 in phosphate buffer pH 7.4 to induce dityrosine
cross-link formation by oxidation. The fibrils were ex-
amined using fluorescence spectrometry and an increas-
ing signal at 400–420 nm corresponding to dityrosine
[36] was observed with time of oxidation (Figure 1a). To
further confirm the presence of dityrosine within the ox-
idized Aβ42 fibrils, the fibrils (prepared in water) were
hydrolyzed using 6 M HCl, 10% TFA, and 1% phenol for
48 h and examined using LC-ESIMS/MS (Figure 1b).
The dityrosine content was identified using transition re-
actions ions 361.1/315 and a retention time of 5.5 min
(Figure 1bii), consistent with that of a dityrosine stand-
ard (Figure 1bi). Negative stain transmission electron
microscopy (TEM) was used to compare oxidized fibrils
with non-oxidized fibrils to evaluate any potential mor-
phological changes to the samples and revealed short,
clumped networks of fibrils in the oxidized sample after
24 hours (Figure 1d) compared to long, straight, and
well dispersed fibrils with diameter of 9.32 nm (SD ±2.1
n = 6) observed in the sample without oxidation and in-
cubated in phosphate buffer only (Figure 1c). This may
suggest that the oxidized fibrils are cross-linked to form
a network and this is consistent with tyrosine residue 10
being exposed on the surface of the fibrils and available
for dityrosine crosslinking between either protofilaments
or perhaps individually crossing fibrils. Structures for
Aβ42 and Aβ 40 fibrils show the tyrosine residue at
position 10 at the end of β-sheet core [4,37] showingtal gyrus tissues were obtained
logical diagnosis
ol case but with Hypoxic-type changes and amyloid angiopathy
ol-minimal ageing changes
imer’s disease HP-tau stage 6 with mild to moderate amyloid angiopathy
imer’s disease HP-tau stage 6 with moderate amyloid angiopathy
imer’s disease HP-tau stage 6 with moderate amyloid angiopathy
imer’s disease HP-tau stage 6 with mild amyloid angiopathy
imer’s disease -modified Braak BNE stage 5
Figure 1 Formation of dityrosine crosslinks in Aβ42 fibrils. Preformed Aβ42 fibrils (20 μM) were incubated in the presence of Cu2+/H2O2 for
72 hours and the appearance of dityrosine detected using fluorescence (a). b) The dityrosine content was confirmed using LC-ESIMS/MS and this
shown with relative abundance on y-axis. i) LC-ESIMS/MS from authentic synthetic dityrosine, ii) hydrolysate from oxidized preformed Aβ42 fibrils, iii)
hydrolysate from Aβ42 fibrils formed under oxidation conditions for three days (the fibrils were obtained from incubation of soluble Aβ42 with
Cu2+/H2O2 in water at 37°C and agitation) (c, d) Electron micrographs showing the morphology of fibrils prior to oxidation (c) and following
24 hour oxidation (d) (diameters approximately 100–150 Å).
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association.
Many recent studies have demonstrated that soluble
Aβ oligomers, rather than Aβ fibrils, are the most toxic
species and disruptive to physiological processes involved
in learning and memory in AD [33,38,39]. Dimeric
species have been isolated from AD brains [40] and
these have also been shown to be toxic [41]. Oligomers
formed by synthetic dityrosine crosslinked dimers have
been shown to be more toxic than corresponding mono-
meric peptide [42]. In order to investigate whether dityr-
osine crosslinks can be formed by soluble Aβ42, freshly
solubilized Aβ42 was incubated up to three days in the
presence and absence of Cu2+ and H202 in phosphate
buffer at pH 7.4 to induce crosslinking as well as to follow
fibrillogenesis. Dityrosine formation was monitored using
fluorescence excitation over three days (Figure 2a,b) and
confirmed by LC-ESIMS/MS (Figure 1biii). The resultingassemblies were also assessed using TEM, Thioflavin
T (ThT) fluorescence and SDS-PAGE.
Fluorescence spectra revealed an increasing dityrosine
fluorescence signal with time in the Aβ42 sample incu-
bated in the presence of Cu2+ and H202 (Figure 2a),
whilst no such signal was observed in the control sample
(Figure 2b). To examine how quickly dityrosine cross-
linking develops, the oxidized sample was monitored
using fluorescence over one hour (Figure 2c) revealing
the presence of dityrosine after only 10 minutes incuba-
tion. In contrast, at an excitation wavelength of 280 nm,
the tyrosine fluorescence signal at 305 nm was observed
to decrease over the incubation time of three days
(Figure 2d). A gradual decrease in tyrosine intensity was
observed for control fibrils (Figure 2d) and this decrease
is thought to correspond to involvement of tyrosine resi-
dues in Aβ42 assembly [43] or could be due to loss of
signal as the fibrils elongate and precipitate. Tyrosine
Figure 2 Monitoring dityrosine and tyrosine fluorescence during Aβ42 assembly. Freshly prepared Aβ42 (20 μM) was incubated in the
presence of Cu2+/H2O2 and monitored by fluorescence over three days (a) and compared to Aβ42 alone (b). Dityrosine fluorescence was
monitored (Ex. 320 nm, Em. 410–420 nm) and a) oxidized Aβ42 shows a strong signal at 24 hours incubation compared to no signal in b) control
Aβ42 sample. The development of the dityrosine signal was monitored at earlier time points (c) using the addition of EDTA and the spectrum
shows a signal at 420 nm following only 10 mins incubation. Tyrosine fluorescence (Ex. 280 nm, Em. 305 nm) was used to follow assembly with
time (d). The intensity at 305 nm is plotted against time. Both conditions show a decrease in fluorescence signal over time for tyrosine, but
oxidized Aβ42 shows a significant reduction after 24 hours, compared to a slow reduction in tyrosine fluorescence that accompanies assembly
for control Aβ42.
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tyrosine signal concurrent with the increase in dityrosine
signal in the oxidized sample following 24 hours incuba-
tion (Figure 2d) at the same time as a strong dityrosine
signal is observed. At time zero, the intensity at 305 nm
is lower for the oxidized sample compared to control
and this is arises from quenching of the signal due to
binding of the Cu2+ to tyrosine. Dityrosine formation
appears to occur early (after only 10 mins) in the assem-
bly process consistent with dityrosine coupling being
present in early oligomeric species. A ThT fluorescence
assay showed an increased signal following 72 hour in-
cubation of both control and oxidized Aβ42 confirming
formation of fibrils in both samples (Figure 3a). How-
ever, the intensity of the signal from control fibrils is sig-
nificantly higher than for oxidized fibrils. This may arise
from the effect of differences in the buffer conditions on
ThT signal or possibly due to the increased association
of fibrils formed by oxidized Aβ42 revealed by electron
microscopy (Figure 4). Following only 10 minutes incu-
bation, SDS gel electrophoresis separation of oxidized
Aβ42 reveals the presence of bands at molecular weights
corresponding to dimer to hexamer (Figure 3b), similar
to those shown by oxidation using PICUP [44], which
supports the view that small Aβ assemblies can be
stabilized by oxidation to dityrosine. In comparison, Aβincubated without oxidation runs as a monomer and a
trimer, but no significant dimer is observed (Figure 3b).
These SDS stable oligomeric species appear to evolve
further and we observe fibrils following 48 incubation
(Figure 4) suggesting that the formation of the cross-
linked dimer could be on pathway for fibril assembly.
To gain further insight into the morphological changes
to Aβ42 fibrils induced by oxidation, samples were ex-
amined using negative stain TEM (Figure 4). Aβ42 im-
mediately following preparation (zero hour) showed
small globular structures consistent with oligomeric
species (5–30 nm) (Figure 4a and 4d). Under oxidation
conditions the freshly dissolved Aβ42 oligomers again
appeared to have a spherical appearance (5–25 nm)
(Figure 4a) and these developed into larger, non-fibrillar
structures after 24 hours (Figure 4b) and then into clus-
tered fibrils after 48 hours (Figure 4c). After incubation
for 24 hours in phosphate buffer only, fibrils were ob-
served with both flat, striated ribbons, and twisted
morphologies (Figure 4e) and these developed further at
48 hours (Figure 4f ). TEM did not reveal any obvious
differences in fibril density between Aβ incubated under
oxidizing and non-oxidizing conditions, although the
oxidized sample appears to show shorter, more self-
associated fibrils, which may be consistent with some
interfibrillar crosslinking. Fibrils were observed following
Figure 3 Thioflavine T fluorescence and SDS PAGE of oxidized and control Aβ42. a) ThT fluorescence spectra following fibril formation from
Aβ42 (20 μM) in the presence or absence of Cu2+ and H2O2 for 72 hours. The spectra for oxidized and control samples show an increased intensity over
the incubation time and show increased ThT signal for non-oxidized compared to oxidized samples. b) SDS PAGE showing separation of Aβ42. Oxidized
Aβ42 (left column) runs as monomer and dimer (approx. 9 kDa, black arrow), whilst non oxidized, control Aβ42 (right column) shows bands corresponding
to monomer and trimer as previously observed [44]. The trimer is thought to be induced by SDS [44]. Densitometry confirms that monomer is the
strongest band following by dimer for oxidized but not control fibrils. This reveals that the dimer is enriched under oxidation conditions.
Figure 4 Transmission electron microscopy images of freshly formed Aβ42 fibrils. 20 μM Aβ42 (pH 7.4) was incubated in the presence of
Cu2+/H2O2 (a, b, c) and compared to 20 μM Aβ42 in phosphate buffer alone (pH 7.4) (d, e, f). Assembly was monitored by electron microscopy
after incubation for (a and d) zero hours, (b and e) 24 hours and (c and f) 48 hours. Both oxidized and control Aβ42 samples show oligomeric
species at zero hour (a, d) and fibrils following 48 hour incubation (c, g). However, at 24 hours (b and f) fibrils were observed in non-oxidized
conditions (f), but no fibrils were observed in oxidised conditions (b). The presence of dityrosine was detected using immunogold labeling using
a dityrosine specific antibody that labeled oxidized fibrils (g) but not control fibrils (h).
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48 hours for the oxidized Aβ42.
In order to examine whether dityrosine crosslinks can
be detected within the amyloid fibrils and to show the
dityrosine distribution, TEM immunogold labeling using a
dityrosine specific monoclonal antibody was performed.
Figure 4e shows anti-dityrosine labeling on Aβ42 fibrils
revealing gold distributed close to the fibrils grown in an
oxidizing environment. Control Aβ42 did not label with
the dityrosine antibody (Figure 4f). Very strong evidence
of dityrosine identity was provided using these specific
monoclonal dityrosine antibodies and these clear differ-
ences between oxidized and control also provides evidence
for the specificity of the antibody. We are not able to rule
out formation of trityrosine, but this would be expected to
further strengthen the fibrils. Mass-spectrometry data
(Figure 1b) shows strong evidence for the presence of
dityrosine. These in vitro findings suggest that conditionsFigure 5 The stability of crosslinked fibrils. a) Oxidized and non-oxidize
prolonged incubation at −80°C showing a strong intensity signal at 420 nm
dissolve the fibrils and the concentration of Aβ42 in solution was compared b
fibrils. c) Electron micrographs of oxidized fibrils before and after formic acid t
formic acid. d) Electron micrographs of non-oxidized fibrils before and after fo
formic acid. Scale bars represent 0.2 μm.similar to oxidative stress can promote the formation of
dityrosine cross-links in self-assembling Aβ42 samples
resulting in a high density within the fibrils. Interestingly,
no fibrils were observed in the oxidized sample at 24 hours
by TEM (data not shown), although there is a very strong
signal by dityrosine fluorescence (Figure 2a & c). This sup-
ports the view that dityrosine cross-links form early in the
assembly process.
Dityrosine crosslinking may lend further stability to the
already stable amyloid fibrils formed. To investigate this
possibility, we compared the stability of oxidized and non-
oxidized Aβ42 amyloid fibrils. Fibrils were stored at −80°C
for over one year. Following thawing, dityrosine content
was assessed using fluorescence and oxidized fibrils were
shown to still contain dityrosine crosslinks after prolonged
freezing, whilst no dityrosine fluorescence was detected
for non-oxidized, frozen fibrils (Figure 5a). Both sets of
fibrils were examined by electron microscopy, and bothd Aβ42 fibrils were examined using dityrosine fluorescence after
for oxidized but not non-oxidized fibrils. b) Formic acid was used to
efore and after formic acid dissolution for oxidized and non-oxidized
reatment showing that the dityrosine crosslinked fibrils are resistant to
rmic acid treatment showing the fibrils are susceptible to damage by
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Aβ42 concentration in the supernatants indicated that
there was more soluble Aβ in the oxidized samples
(Figure 5b). The fibril pellets were treated with formic acid
to dissolve fibrils and the amount of peptide released into
the supernatant was compared between the oxidized and
non-oxidized samples (Figure 5b). The concentration of
Aβ found in the supernatant following formic acid treat-
ment was very significantly lower in oxidized sample com-
pared to the non-oxidized sample (0 versus 14.8 μM),
suggesting that the oxidized fibrils were resistant to dissol-
ution with the acid (Figure 5b). Electron microscopy
revealed that the oxidized fibrils were shortened, but
remained at a broadly similar concentration when com-
pared to amounts prior to oxidation. Those that had not
been oxidized were narrower and much more difficult
to find on the grid (Figure 5c and d). These results seem
to support the view that the dityrosine crosslinking
strengthens the fibrils and these fibrils become more re-
sistant to acid dissolution following oxidation.
Aβ42 is internalized into neuroblastoma cells and
becomes dityrosine crosslinked
In previous work, we have shown that freshly prepared
Aβ42 can be internalized into SH-SY5Y neuroblastoma
cells and accumulates over 24 hours in lysosomal com-
partments [33]. We were interested to investigate whether
the Aβ42 administered to these cells formed dityrosineFigure 6 Immunogold labeling TEM showing neuroblastoma cells tre
(10 nm) and Aβ42 (5 nm) labeling within the lysosomes of treated cells. b)
treated, control cells, but no Aβ labeling was observed. c) Cells were obser
(10 nm). White arrows are used to highlight the fibrillar material. Inserts shocrosslinks during incubation in contact with neuro-
blastoma cells. Cells were treated in an identical way
to previous experiments [33], administered with a final
concentration of freshly solubilized 10 μM Aβ42 and incu-
bated for 24 hours. Sectioned cells were co-labeled with
the mouse monoclonal dityrosine antibodies and rabbit
polyclonal Aβ antibodies for Aβ42 fibrils. Previously, a
monoclonal, conformational specific antibody was used to
detect Aβ [33]. For the purpose of this study, secondary
antibodies were 5 nm gold conjugated goat anti-rabbit
IgG and 10 nm gold conjugated goat anti-mouse IgG,
allowing the identification of both Aβ (5 nm) and dityro-
sine (10 nm) respectively in the sectioned cells and the
opportunity to detect whether they co-localized. TEM of
sectioned neuroblastoma cells treated with Aβ42 confirms
the appearance of internalized Aβ42 concentrated in lyso-
somal regions (Figure 6a), as shown previously [33]. Close
examination also showed that dityrosine and Aβ42 were
co-localized together inside the lysosomes (Figure 6a).
Examination of control cells showed some labeling of
dityrosine within lysosomes, but no co-localization with
Aβ labeling (Figure 6b). Further investigation revealed the
presence of fibrillar Aβ42 around and within the cells,
where the fibrils exhibited clear co-localization of dityro-
sine and Aβ (Figure 6c). This suggests that Aβ is cross-
linked both inside and outside of the neuroblastoma cells.
Occasionally extracellular Aβ was observed to be entering
the cells at the plasma membrane (Figure 7) and againated with 10 μM oligomeric Aβ. a) The images reveal dityrosine
low level dityrosine labeling was observed within lysosomes in vehicle
ved containing fibrillar Aβ labeled for both Aβ (5 nm) and dityrosine
w magnified images for further clarity.
Figure 7 Electron micrographs of sections of Aβ42 treated neuroblastoma cells showing immunogold labeling of Aβ (5 nm) and
dityrosine (10 nm). The images reveal colabeled fibrils outside and also inside the cells and highlight internalization at the plasma membrane
(top left panel). The figure shows magnified images in the bottom two panels for extra clarity.
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Taken together, these results suggest that the externally
administered Aβ42 becomes oxidized during incubation
in the cellular environment and that dityrosine crosslinked
oligomers (and possibly fibrils) can be internalized into
lysosomes.
The presence of dityrosine within plaques in AD brain
We have established that Aβ42 is able to undergo oxida-
tion leading to formation of dityrosine crosslinks in vitro
and in a cellular environment. To determine the possible
physiological relevance of dityrosine formation in the Aβ
accumulation in AD brain, immunogold labeling TEM
was carried out to detect any co-localization of Aβ and
dityrosine in AD brain and compared to age matched
control brain. Previously dityrosine has been detected
and quantified in AD brain [5]. Using HPLC with elec-
trochemical array detector (HPLC-ECD), dityrosine was
quantified in four regions of the AD brain [5]. It was re-
ported that dityrosine levels were elevated significantly
in the hippocampus and neocortical regions of the AD
brain. However, no previous study has successfully de-
tected dityrosine in plaques, and no cellular localization
study of dityrosine in human brain has been reported be-
fore. Immunogold labeling using anti-dityrosine antibodywas performed on brain sections taken from AD patients
and control subjects (see Table 1), which revealed a high
density of dityrosine within amyloid plaques in AD brain
sections (Figure 8a and c). A control was performed using
an irrelevant antibody (to hair cell antigen) at identical an
IgG concentration and showed virtually no labeling (<<1
gold particles/micron) (Figure 8b) compared to the serial
section showing dityrosine/Aβ labeling of the same plaque
in Figure 8a (showing 100 gold particles/micron2).
Figure 8c shows images revealing the clear labeling of the
fibrillar component of the amyloid plaques with the dityr-
osine antibody (Figure 8ciii), indicating that the fibrils
themselves contain dityrosine. Double immunogold la-
beling TEM was also used to confirm that the amyloid
plaques labeled with the anti-Aβ antibody as well as anti-
dityrosine (Figure 8di and diii) and this is highlighted by
processing of the images to show different sized labels in
red and blue in Figure 8e. The numbers of large (dityro-
sine) and small (Aβ) gold particles were compared be-
tween the amyloid plaque area and areas around the
plaques and showed a level of 100 and 90 gold particles/
micron2 for dityrosine and Aβ respectively over plaque
areas. In comparison, the non-plaque areas showed only 2
gold particles/micron2 for both labels. Two additional AD
patient brains were also examined and these are shown in
Figure 8 Immunogold labeling TEM within amyloid plaques from AD brains. a) Shows double labeling using the dityrosine antibody and
anti-Aβ antibody on an AD brain section and reveals very dense labeling of the amyloid plaques. This is compared to a serial section b) Showing
single labelling using an irrelevant antibody against hair cell antigen (HCA) to show the specificity of the dityrosine labeling on plaques. This
image shows virtually no gold labeling. c) Shows single labeling using the dityrosine antibody to reveal very clear labeling at increasing magnification
(ci, cii and ciii) showing that the dityrosine labels fibrils in the plaques. d) Double labeling with anti-Aβ (5 nm) and anti-dityrosine (10 nm)
confirms colocalisation of dityrosine with Aβ within amyloid plaques at increasing magnifications (di and dii). e) Shows the 10 nm labeling for
dityrosine highlighted in red and 5 nm labeling for Aβ in blue. Inserts show magnified images for further clarity. f) and g) show additional
examples of co-immunogold labeling in brain from additional patients.
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plaques. These results show the high density, specific
localization of dityrosine within plaques (Figure 8) and
strong evidence for colocalisation with Aβ, suggesting a
potentially important role for dityrosine in amyloid accu-
mulation in amyloid plaques.
Dityrosine as a potential biomarker of oxidative
stress in AD
Given our results showing the colocalisation of antibodies
against dityrosine and Aβ over amyloid fibrils deposited in
Alzheimer’s brains and images showing that neuroblast-
oma cells incubated with Aβ42 show dityrosine-Aβ colo-
calisation over fibrillar material and in lysosomes, we were
interested to see if dityrosine crosslinked Aβ could be
identified in cerebrospinal fluid (CSF) and could therefore
be a useful biomarker for Alzheimer’s disease.Here, TEM immunogold labeling for dityrosine was
used to detect dityrosine and gain a general view of pro-
tein oxidation represented by dityrosine in CSF of AD
and healthy age-matched control subjects. TEM immu-
nogold colabeling/negative staining of CSF reveals a
higher density of dityrosine and Aβ labeling in CSF
taken from three AD patients (Table 1) (Figure 9a) com-
pared to age matched controls (Table 1) (Figure 9b).
Overall there was a much higher density of labeling for
both Aβ and dityrosine in AD CSF compared to con-
trols, highlighting the presence of Aβ and also showing
the increased level of dityrosine crosslinked proteins in
AD CSF. In the CSF from AD patients, two different
areas of labeling were observed: those with low-density
co-localization, and others showing high-density co-
localisation of dityrosine and Aβ indicating that the Aβ
found in CSF may contain dityrosine crosslinks, but also
Figure 9 Immunogold labeling TEM/negatively stain of cerebrospinal fluid from AD brains and age matched controls. a) A higher
density of dityrosine (labeled with 15 nm) and Aβ (labeled with 5 nm) labeling was observed for CSF from an AD patient (top images) compared
to b) age matched control. In CSF of AD patients, we can identify two different areas of labeling, low-density co-localization (☐), and high density
co-localization (◯) of dityrosine and Aβ. We observe significant labeling levels for AD CSF compared to virtually no labeling in CSF from control
patients. Inserts show magnified images for further clarity.
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in AD CSF.
Discussion
Our results have shown that dityrosine crosslinks form
in preformed Aβ42 fibrils and in oligomeric Aβ incu-
bated under oxidizing conditions in the presence of Cu2+
and H2O2. We have also confirmed that the dityrosine
crosslinked Aβ has the capability to assemble further to
form amyloid fibrils. It has been shown previously that
1:1 Cu2+: Aβ molar ratios and above are the most effi-
cient ratios to form dityrosine cross-links [45], demon-
strating that Cu2+: Aβ molar ratio is a critical factor in
controlling the aggregation state of Aβ42. We have
shown that oxidized Aβ forms stabilized dimer and
tetramer and these might represent small oligomeric
species that are isolated from AD brain [41]. We hy-
pothesise that the brain derived dimer may be stabilized
by dityrosine crosslinks [41,42] and work is on going to
confirm this. Here we show that fibrils are stabilized by
dityrosine crosslinking. Moreover, it has been shown
that sub-stoichiometric Aβ42-Cu2+ (10:1) complexes
can be toxic to cells [46] and recent work has shown
that non-aged and aged molar ratios of 1:1 Aβ42-Cu2+
are neurotoxic, whilst Aβ42-Cu2+ complexes prepared
at sub and supra-equimolar ratios were nontoxic to
neuronal cells [22,45]. Aβ peptide can coordinate withCu2+ to give Aβ-Cu2+ complexes [47,48], which are redox-
active. In turn, these complexes show ability to induce
ROS formation, resulting in oxidative stress [16,22]. Cu2+
ions coordinate to Aβ via the three histidine residues His6,
His13, and His14 to form a histidine bridge [17,49-51] and
produce SDS-resistant oligomers [20]. Recent work has
shown that Tyr10 is not directly bound to Cu2+ [51] but
that the tyrosine cross-linking is promoted by the histidine
bridge formation with Cu2+ [22]. Taken together, we sug-
gest that dityrosine crosslinking of Aβ could be nucleus
for assembly and aggregation to form toxic oligomeric
species and amyloid fibrils (Figure 10). An alternative
route to dityrosine formation is via myeloperoxidase
[52], a peroxidase shown to be associated with Aβ in se-
nile plaques in AD brain tissue [53].
Here, cell culture experiments show that conditions
amenable to Aβ dityrosine crosslinking are also present
in a cellular environment and that dityrosine crosslinked
Aβ fibrils are found around cells and internalized into
cells. Aβ and dityrosine co-localize within lysosomes. In
previous work, we have shown that internalized oligo-
meric Aβ42 leads to accumulation of autophagosomes
containing Aβ. Considerable evidence supports the view
that intralysosomal Aβ accumulation can induce neuronal
death [54-56] and here we have shown that oligomers and
fibrils can be stabilized by dityrosine crosslinking. Studies
using Aβ42 with the tyrosine 10 substituted for alanine
Figure 10 Schematic summarizing the mechanism of dityrosine formation in Aβ in complex with copper including the generation of
ROS and summarizing the results showing the physiological importance of dityrosine crosslinked Aβ in Alzheimer’s disease.
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and prevented toxicity to primary cortical neurons sup-
porting the view that dityrosine crosslinking may be im-
portant in mediating oligomer toxicity [57]. Here, electron
micrographs show the internalization of dityrosine cross-
linked Aβ fibrillar material into the cytoplasm (Figure 7)
and into lysosomes (Figure 6). The oligomeric Aβ may be
stabilized by covalent crosslinks and provide a stable
nucleus for assembly (Figure 10).
Oxidative stress has been widely implicated in AD
pathogenesis. Sources of ROS, such as H2O2, superoxide
anion, and hydroxyl radical, can be formed from differ-
ent in vivo sources (e.g. trace metals, photochemical,
and enzymatic reactions) although mitochondria repre-
sent the main in vivo source of ROS formation [58]. At
the same time mitochondria are the main target of ROS
attack [59], resulting in the formation of peroxidized,
undegradable macromolecules. H2O2 can easily diffuse
into lysosomes and react with iron ions that are released
from the degradation of different metalloproteins during
their intralysosomal degradation. The interaction of H2O2
with iron ions results in the formation of the highly re-
active hydroxyl radicals. The latter would attack intraly-
sosomal macromolecules, such as Aβ, causing cross-
linking of these materials. The oxidative modification
especially cross-linking of autophagocytosed material, is
the most probable cause of non-degradability of these
materials. The excessive accumulation of these non-
digested materials could result in endosomal/lysosomalleakage and as a consequent acid hydrolase enzymes will
be released and ultimately leading to cell death [56]. Re-
cently, Murakami and Shimizu have clarified the role of
cytoplasmic superoxide radical as a possible contributing
factor to intracellular Aβ oligomerization in AD [60]. It
also has been suggested that intraneuronal Aβ oligomers
cause neuronal death by activating endoplasmic reticulum
stress, endosomal/lysosomal leakage and mitochondria
dysfunction [61,62]. Kurz et al., (2008) [63] have high-
lighted a close relation between lysosomes and mito-
chondria, explaining that accumulation of iron inside
mitochondria will result in lysosomal iron loading as a
consequence of degradation of mitochondria by lyso-
somal enzymes. Moreover, normal production of H2O2
by mitochondria results in oxidative stress, which will
labilize lysosomes, and further oxidative stress could
result from degradation of mitochondria by lysosomal
enzymes.
We have shown that amyloid plaques in AD brain tis-
sue show extensive dityrosine crosslinking and this may
suggest that these highly stable insoluble deposits are
stabilized by the covalent crosslinking resulting in a re-
sistance to degradation. Therefore, the existence of dityr-
osine may be relevant in AD pathology. Friedrich et al.,
(2010) [64] have shown that Aβ internalized to cultured
cells can accumulate and assemble resulting in eventual
cell death and thus they suggest that the formation of
amyloid plaques might arise from accumulated intracel-
lular Aβ. Therefore, there may be a pathway from the
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crosslinked Aβ that we have observed in neuroblastoma
cells to the eventual deposition as amyloid plaques com-
posed of dityrosine crosslinked Aβ observed here in AD
tissue. Previous work has revealed that dimeric (9 kDa)
Aβ can be isolated from human AD brain [65] and this
may be a crosslinked dimer. In future work, it would be
important to fully characterize these dimers.
Clioquinol is a potent Cu/Zn chelator and has been
shown to significantly reduce Aβ amyloid deposition in
an APP transgenic mouse [66] and has shown some effi-
cacy in human AD subjects [67]. These studies have
been taken to suggest that copper plays a very significant
role in Aβ deposition in AD and could imply that dityro-
sine formation can stabilize deposits.
A few studies have previously attempted to quantify
dityrosine in cerebrospinal fluid. Techniques including
HPLC with electrochemical array detection (HPLC-ECD)
or fluorescence detection, and liquid chromatography with
triple quadrapole mass spectrometric detection (LC-MS/
MS) have been applied to quantify dityrosine concentra-
tions in CSF sample from both healthy and disease af-
fected subjects [5,68,69]. However, the results of these
studies have been conflicting, perhaps due to differences
in sample handling and preparation before measuring.
Quantitative screening of protein glycation, oxidation and
nitration adducts in CSF of AD and healthy age-matched
subjects has been taken to suggest that dityrosine con-
centration do not change in AD patients with respect to
control subjects [68]. By contrast, earlier studies using
electrochemical detection showed that dityrosine concen-
tration was elevated markedly in CSF of AD patients [5].
Studies have suggested that CSF is depleted of Aβ in AD
patients, however, careful consideration of the results
shows highly variable amounts of Aβ in CSF from patients
[70]. Here we clearly show, using a specific antibody
against the free N-terminus of Aβ42, that Aβ more abun-
dant within AD CSF relative to the age matched controls.
Our results have revealed very strong evidence for the
presence of both Aβ and dityrosine in CSF from AD pa-
tients and both Aβ and dityrosine are very rarely observed
in CSF from age-matched controls. Although this observa-
tion needs to be further substantiated with further AD
cases, this points to the possible use as a potential bio-
marker for AD.Conclusions
At equimolar ratio of Cu2+ and Aβ42, Cu2+ can catalyze
tyrosine oxidation by H2O2, leading to dityrosine cross-
link generation, and the latter can cause Aβ misfolding,
resulting in Aβ assembly into oligomers and subsequently
into amyloid fibres. The dityrosine cross-links stabilize Aβ
fibres once formed.Here we present a comprehensive study of in vivo and
in vitro dityrosine cross-linking associated with Aβ. We
have revealed the presence of dityrosine cross-links in
amyloid plaques in human AD brain, and also in CSF,
and identified significant relationships between dityrosine
cross-links and amyloid deposit formation. The in vitro
and in vivo results presented here reveal that oligomeric
Aβ can undergo oxidative modification in a cellular envir-
onment, resulting in cross-linked Aβ through dityrosine
followed by intralysosomal Aβ accumulation that could
lead to lysosomal leakage and cell death. Our results show
the significant accumulation of dityrosine crosslinked Aβ
in amyloid plaques, implying a role in stabilization of these
insoluble deposits. We have also shown a potential bio-
marker for AD in CSF, which contains elevated dityrosine
crosslinked proteins as well as elevated dityrosine cross-
linked Aβ (Figure 9). Research is ongoing to further
characterize the crosslinked Aβ as a biomarker in CSF.
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